Telomerase in endocrine and endocrine-dependent tumors

Journal of Steroid Biochemistry and Molecular Biology

Volumn 78, Issue 3, 2001, Pages 201-214

  Orlando, C ^a   Gelmini, S ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Endocrine; Telomerase; Tumor

Indexed keywords

ANDROGEN; TAMOXIFEN; TELOMERASE;

BREAST CANCER; CANCER THERAPY; ENZYME ACTIVITY; ENZYME INHIBITION; HORMONAL REGULATION; HUMAN; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; PARATHYROID CARCINOMA; PHEOCHROMOCYTOMA; PROSTATE CARCINOMA; REVIEW; THYROID CARCINOMA;

EID: 0034796776     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(01)00101-7     Document Type: Short Survey

References (168)

1. Telomerase activity in human solid tumors
2. Structure and function of telomeres
3. Telomeres, telomerase and cancer: Is the magic bullet real?
4. Telomeres, telomerase, and myc. An update
5. Role of telomerase in cellular proliferation and cancer
6. A critical role for telomeres in suppressing and facilitating carcinogenesis
7. Telomeric localization of TRF2, a novel human telobox protein
8. Control of telomere lenght by the human telomeric protein
9. Control of human telomere lenght by TRF1 and TRF2
10. Mammalian telomeres and in a large duplex loop
11. Life and cancer without telomerase
12. Telomerase activity in human germline and embryonic tissues and cell
13. Applications of telomerase research in the fight against cancer
14. Multiple pathways for the regulation of telomerase activity
15. Cellular senescence and cancer
16. Telomeres and telomerase: Biological and clinical importance
17. Mammalian telomeres and telomerase
18. The telomere and telomerase: How do they interact?
19. Telomeres and telomerase
20. Bladerunners and telomerases
21. Telomeres, telomerase and cancer
22. Role of telomerase in normal and cancer cells
23. Telomeres, telomerase and cancer: An up-date
24. Specific association of telomerase activity with immortal cells and cancer
25. Telomerase activity in human breast tumors
26. Telomerase activity in benign and malignant thyroid tumors
27. Application of telomerase assay for the screening of cervical lesions
28. Telomerase activity: A marker to distinguish follicular thyroid adenoma from carcinoma
29. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity
30. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol [TRAP]
31. Enhanced detection of human telomerase activity
32. Rapid, nonisotopic assay for the quantitation of telomerase activity in human tumor specimens
33. Telomerase activity is significantly enhanced in malignant adrenocortical tumors in comparison to benign adrenocortical adenomas
34. Comparison of telomerase activity in bladder carcinoma and exfoliated cells collected in urine and bladder washings, using a quantitative assay
35. Real-time quantification of human telomerase reverse transcriptase mRNA in tumors and healthy tissues
36. Estrogen activates telomerase
37. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells
38. Expression of telomerase activity in human endometrium is localized to epithelial glandular cells and regulated in a menstrual phase-dependent manner correlated with cell proliferation
39. Effects of tamoxifen on telomerase activity in breast carcinoma cell lines
40. Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system
41. Progesterone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway
42. Effects of androgens of telomerase activity in normal and malignant prostate cells in vitro
43. Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone
44. 3: A new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells
45. Telomerase activity in human breast tumors
46. Telomerase activity in human breast cancer and benign breast lesions: Diagnostic applications in clinical specimens, including fine needle aspiratesm
47. Telomerase activity is associated with cell cycle deregulation in human breast cancer
48. Telomerase expression in human breast cancer with and without lymph node metastases
49. Telomerase activity and survival of patients with node-positive breast cancer
50. Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer
51. Detection of telomerase activity in breast masses by fine-needle aspiration
52. Telomerase activity in benign and malignant breast lesions: A pilot prospective study on fine-needle aspirates
53. Telomerase activity in human proliferative breast lesions
54. Carefull histological confirmation and microdissection reveal telomerase activity in otherwise telomerase-negative breast cancers
55. Telomerase enzyme activity and RNA expression during the multistage pathogenesis of breast carcinoma
56. Telomerase activity in relation to p53 status and clinico-pathological parameters in breast cancer
57. Analysis of telomerase activity levels in breast cancer: Positive detection at the in situ breast carcinoma stage
58. Telomerase activity in normal and neoplastic breast
59. Telomerase activity and prognosis in breast cancer
60. Telomerase activity in ductal carcinoma in situ and invasive breast cancer
61. Telomerase activity in phyllodes tumours
62. The association between telomerase, histopathological parameters, and KI-67 expression in breast cancer
63. Changes of telomerase and telomere lengths in paired normal and cancer tissues of breast
64. Genetic changes associated with telomerase activity in breast cancer
65. Telomerase activity and prognosis in primary breast cancers
66. Telomerase is a highly sensitive and specific molecular marker in fine-needle aspirates of breast lesions
67. Telomerase activity in ductal carcinoma in situ of the breast
68. Telomerase activity and lymphovascular invasion in breast cancer
69. Telomerase activity as a marker of breast carcinoma in fine-needle aspirated samples
70. Frequent amplification of the telomerase reverse transcriptase gene in human tumors
71. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay
72. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients
73. Telomerase RNA as a detection marker in the serum of breast cancer patients
74. Telomerase activity in needle biopsies from prostate cancer and benign prostates
75. Focal intratumoral heterogeneity for telomerase activity in human prostate cancer
76. Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma
77. Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia [PIN]
78. Detection of telomerase activity in prostate needle-biopsy samples
79. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium
80. Detection of telomerase activity in prostate cancer by needle biopsy
81. Telomerase activity in human benign prostate tissue and prostatic adenocarcinomas
82. Detection of telomerase activity in human prostate: A diagnostic marker for prostatic cancer?
83. Telomerase activity in primary prostate cancer
84. Telomerase activity: A prevalent marker of malignant human prostate tissue
85. An appraisal of telomerase activity in benign prostatic hyperplasia
86. htert expression correlate with MYC over-expression in human prostate cancer
87. Expression of the RNA component of human telomerase [hTR] in prostate cancer, prostatic intraepithelial neoplasia and normal prostate tissue
88. Evaluation and management of the solid thyroid nodule
89. Fine-needle aspiration of the thyroid: An appraisal
90. Telomerase activity in human thyroid carcinomas originating from the follicular cells
91. Significant correlation of telomerase activity in thyroid papillary carcinomas with cell differentiation, proliferation and extrathyroidal extension
92. Telomerase activity in the differential diagnosis of papillary carcinoma of the thyroid
93. Telomerase activity in benign and malignant thyroid diseases
94. Telomerase activity in benign and malignant human thyroid tissues
95. Telomerase activity in lesions of the thyroid: Application to diagnosis of clinical samples including fine-needle aspirates
96. Decrease of telomere length in thyroid adenomas without telomerase activity
97. Human telomerase reverse transcriptase [hTERT] gene expression in thyroid neoplasms
98. Comparison of telomerase and CD44 expression as diagnostic tumor markers in lesions of the thyroid
99. Telomerase activity in thyroid malignancy
100. Telomerase activity and telomere length in benign and malignant human thyroid tissues
101. Telomerase activity in normal leukocytes and in hematological malignancies
102. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells
103. Human telomerase reverse transcriptase [hTERT] gene expression in FNA samples from thyroid neoplasms
104. Teleomerase repeat amplification protocol [TRAP]: A new molecular marker for parathyroid carcinoma
105. Telomerase activity as an indicator of potentially malignant adrenal tumors
106. Genetic changes in human adrenocortical carcinomas
107. Elevated levels of telomerase activity in malignant pheochromocytoma
108. Telomerase activity in adrenal cortical tumors and pheochromocytomas with reference to clinicopathologic features
109. Telomerase activity in the differentiation of benign and malignant adrenal tumors
110. Telomerase activity in benign and malignant adrenal tumors
111. Pheocromocitoma
112. Spontaneous regression of neuroblastoma
113. Do infants with stage IV-S neuroblastoma need treatment?
114. Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas
115. Amplification of N-myc in untrated human neuroblastomas correlates with advanced diseases stage
116. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma
117. Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome
118. Correlating telomerase activity levels with human neuroblastoma outcomes
119. Telomerase activity in neuroblastoma: Is it a prognostic indicator of clinical behaviour?
120. Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas
121. Telomerase activity distinguishes between neuroblastomas with good and poor prognosis
122. Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: A molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues
123. Rapid detection of MYCN gene amplification and telomerase expression in neuroblastoma
124. Prognostic impact of telomerase activity in patients with neuroblastoma
125. Telomerase activity by TRAP assay and telomerase RNA [hTR] expression are predictive of outcome in neuroblastoma
126. Telomerase activity as a prognostic factor in neuroblastomas
127. The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors
128. Telomerase expression in primary neuroblastomas
129. Telomerase activity in small cell and non-small-cell lung cancers
130. Telomerase activity in pulmonary neuroendocrine tumors: Correlation with histologic subtype [MS-0060]
131. Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinoma
132. Is small cell lung carcer the perfect target for anti-telomerase treatment?
133. Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors
134. Evidence for elevated telomerase activity in small cell carcinoma of the bladder
135. Telomerase activity in pancreatic endocrine tumours: A potential marker for malignancy
136. Novel anticancer drug discovery
137. Telomerase as a possible target for anticancer therapy
138. Telomerase activity in normal and malignant mammalian tissues: Feasibility of telomerase as a target for cancer chemotherapy
139. Telomerase as an anti-cancer drug target: Will it fulfil its early promise?
140. Telomerase as an anti-cancer target: Current status and future prospects
141. Telomerase. A target for anticancer therapy
142. Telomerase: The search for a universal cancer vaccine
143. Telomerase: A therapeutic target for the third millennnium?
144. Target therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA
145. The RNA component of human telomerase
146. Antisense telomerase treatement: Induction of two distinct pathways, apoptosis and differentiation
147. Telomerase inhibition by induced expression of antisense RNA
148. Inhibition of human telomerase by a retrovirus expressing telomeric antisense RNA
149. Inhibition of human telomerase activity by peptide nucleic acids
150. Cellular delivery of peptide nucleic acids and inhibition of human telomerase
151. Identifications of determinants of inhibitor binding within the RNA active site of human telomerase using PNA scanning
152. The 5′-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity
153. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells
154. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells
155. Synthetic 2′-O-methyl-modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity
156. Effects of reverse transcriptase inhibitors of telomere length and telomerase activity in two immortalized human cell lines
157. Irreversible telomere shortening by 3′-azido-2′,3′-dideoxythymidine [AZT] treatement
158. Human telomerase inhibition by 7-deaza-2′-deoxypurine nucleoside triphosphates
159. Telomerase from human leukemia cells: Properties and its interaction with deoxynucleoside analogues
160. Reverse transcriptase inhibitors suppress telomerase function and induce senescence-like processes in cultured mouse fibroblast
161. Detection of telomerase in chinese hamster V79 cells and inhibition by 7-deaza-deoxy guanosine triphosphate and [TTAGGG]4 in vitro
162. G-Quadruplex DNA as a target for drug design
163. Effects of cationic porphirins as G-quadruplex interactive agents in human tumor cells
164. Cationic porphirins as telomerase inhibitors: The interaction of tera-[N-methyl-4-pyridyl]porphine with quadruplex DNA
165. Inhibition of human telomerase by a G-quadruplex-interactive compound
166. 1,4- and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase
167. NMR-based model of telomerase-inhibiting compound bound G-quadruplex DNA
168. Toward identifying a cellular determinant of telomerase repression